OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011–2022 Update
Marianna Rogowska, MARY E. THORNTON, Byron Creese, et al.
Drugs & Aging (2022) Vol. 40, Iss. 1, pp. 21-32
Open Access | Times Cited: 46
Marianna Rogowska, MARY E. THORNTON, Byron Creese, et al.
Drugs & Aging (2022) Vol. 40, Iss. 1, pp. 21-32
Open Access | Times Cited: 46
Showing 1-25 of 46 citing articles:
Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study
Pearl L. H. Mok, Matthew Carr, Bruce Guthrie, et al.
BMJ (2024), pp. e076268-e076268
Open Access | Times Cited: 27
Pearl L. H. Mok, Matthew Carr, Bruce Guthrie, et al.
BMJ (2024), pp. e076268-e076268
Open Access | Times Cited: 27
A brain DNA co‐methylation network analysis of psychosis in Alzheimer's disease
Morteza Kouhsar, Luke Weymouth, Adam R. Smith, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access | Times Cited: 1
Morteza Kouhsar, Luke Weymouth, Adam R. Smith, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access | Times Cited: 1
Antipsychotics and Risks of Cardiovascular and Cerebrovascular Diseases and Mortality in Dwelling Community Older Adults
Sylvie Perreault, Laurie-Anne Boivin Proulx, Judith Brouillette, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 178-178
Open Access | Times Cited: 6
Sylvie Perreault, Laurie-Anne Boivin Proulx, Judith Brouillette, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 178-178
Open Access | Times Cited: 6
Nanosystems for Brain Targeting of Antipsychotic Drugs: An Update on the Most Promising Nanocarriers for Increased Bioavailability and Therapeutic Efficacy
Maria Daniela Ferreira, Joana Duarte, Francisco Veiga, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 678-678
Open Access | Times Cited: 15
Maria Daniela Ferreira, Joana Duarte, Francisco Veiga, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 678-678
Open Access | Times Cited: 15
The Relationship Between Antipsychotics, Cognitive Enhancers, and Major Adverse Cardiovascular/Cerebrovascular Events (MACCE) in Older Adults with Behavioral and Psychological Symptoms of Dementia
Haylie M. DeMercy, Colleen A. Brenner
Drugs & Aging (2024) Vol. 41, Iss. 10, pp. 847-858
Open Access | Times Cited: 5
Haylie M. DeMercy, Colleen A. Brenner
Drugs & Aging (2024) Vol. 41, Iss. 10, pp. 847-858
Open Access | Times Cited: 5
Improving Medication-Related Safety for Residents in Nursing Homes: A Qualitative Study
Bianca Shieu, Ya‐Wen Lee, Fayron Epps, et al.
Journal of Gerontological Nursing (2025), pp. 1-6
Closed Access
Bianca Shieu, Ya‐Wen Lee, Fayron Epps, et al.
Journal of Gerontological Nursing (2025), pp. 1-6
Closed Access
Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review
Nokwanda N. Ngcobo
Clinical Pharmacokinetics (2025)
Open Access
Nokwanda N. Ngcobo
Clinical Pharmacokinetics (2025)
Open Access
What Happens Behind Closed Doors? Investigating Care Practices in Nursing Home and Assisted Living Memory Care Units
Amy Elliot, John R. Bowblis, Ian Nelson, et al.
Health Affairs Scholar (2025) Vol. 3, Iss. 2
Open Access
Amy Elliot, John R. Bowblis, Ian Nelson, et al.
Health Affairs Scholar (2025) Vol. 3, Iss. 2
Open Access
Exploring Potential Medications for Alzheimer’s Disease with Psychosis by Integrating Drug Target Information into Deep Learning Models: A Data-Driven Approach
Oshin Miranda, Chen Jiang, Xiguang Qi, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1617-1617
Open Access
Oshin Miranda, Chen Jiang, Xiguang Qi, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1617-1617
Open Access
“I Must Be the One to Change; He’s Doing the Best He Can”: Care Partner Evaluation Results from a Four-Part, In-Person, Dementia Community Education Program
Olivia C. Rubio, Erica K. Husser, Rollin Wright, et al.
International Journal of Environmental Research and Public Health (2025) Vol. 22, Iss. 2, pp. 295-295
Open Access
Olivia C. Rubio, Erica K. Husser, Rollin Wright, et al.
International Journal of Environmental Research and Public Health (2025) Vol. 22, Iss. 2, pp. 295-295
Open Access
Brain Health for All? Influence of Glycemic Control and Neuropsychiatric Symptoms in Dementia with Lewy Bodies: A Case Report and Literature Review
Patrick Stancu, Duarte Janela, Samuel Gurary, et al.
Clinical and Translational Neuroscience (2025) Vol. 9, Iss. 1, pp. 8-8
Open Access
Patrick Stancu, Duarte Janela, Samuel Gurary, et al.
Clinical and Translational Neuroscience (2025) Vol. 9, Iss. 1, pp. 8-8
Open Access
Carbon-based nanomaterials: interactions with cells, brain therapies, and neural sensing
Lorena Gárate-Vélez, Mildred Quintana
Deleted Journal (2025) Vol. 20, Iss. 1
Open Access
Lorena Gárate-Vélez, Mildred Quintana
Deleted Journal (2025) Vol. 20, Iss. 1
Open Access
Gradual dose reduction versus abrupt deprescription of antipsychotic in patients with dementia: A systematic review
Arturo Cortés Cuevas, Eva Martín-Ruiz, Antonio Olry de Labry Lima
Ars Pharmaceutica (Internet) (2025) Vol. 66, Iss. 2, pp. 233-246
Open Access
Arturo Cortés Cuevas, Eva Martín-Ruiz, Antonio Olry de Labry Lima
Ars Pharmaceutica (Internet) (2025) Vol. 66, Iss. 2, pp. 233-246
Open Access
Efficacy of Add-on Agomelatine on Agitation, Aggression, and Neuroprotection in Alzheimer's Disease: A Randomized, Blinded, Controlled Trial
Alireza Kargar, Delara Hazegh Fetratjoo, Reihaneh Moattar, et al.
American Journal of Geriatric Psychiatry (2025)
Closed Access
Alireza Kargar, Delara Hazegh Fetratjoo, Reihaneh Moattar, et al.
American Journal of Geriatric Psychiatry (2025)
Closed Access
Escitalopram for agitation in Alzheimer’s dementia: a randomized controlled phase 3 trial
Tarek K. Rajji, Sheriza Baksh, David Shade, et al.
Nature Medicine (2025)
Closed Access
Tarek K. Rajji, Sheriza Baksh, David Shade, et al.
Nature Medicine (2025)
Closed Access
Predictors and Moderators of Hospitalisation and Mortality in People with Dementia Using Antipsychotics: Systematic Review
Timothy C. Tan, E. Lau, Thuc Duy Le, et al.
Drugs & Aging (2025)
Open Access
Timothy C. Tan, E. Lau, Thuc Duy Le, et al.
Drugs & Aging (2025)
Open Access
Impact of potentially inappropriate psychotropic medicines on falls among older adults in 23 residential aged care facilities in Australia: a retrospective longitudinal cohort study
Narjis Batool, Magdalena Z. Raban, Karla Seaman, et al.
BMJ Open (2025) Vol. 15, Iss. 4, pp. e096187-e096187
Open Access
Narjis Batool, Magdalena Z. Raban, Karla Seaman, et al.
BMJ Open (2025) Vol. 15, Iss. 4, pp. e096187-e096187
Open Access
Schizophrenie im Alter
Detlef Wietelmann
Geriatrie up2date (2025) Vol. 07, Iss. 02, pp. 93-112
Closed Access
Detlef Wietelmann
Geriatrie up2date (2025) Vol. 07, Iss. 02, pp. 93-112
Closed Access
Affiliate Stigma among family caregivers of individuals with dementia in China: a cross-sectional study
Yingying Shi, Shishi Dong, Zhiqi Liang, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 2
Yingying Shi, Shishi Dong, Zhiqi Liang, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 2
What clinical analysis of antipsychotic-induced catatonia and neuroleptic malignant syndrome tells us about the links between these two syndromes: A systematic review
Jordan Virolle, Maximilien Redon, François Montastruc, et al.
Schizophrenia Research (2023) Vol. 262, pp. 184-200
Closed Access | Times Cited: 5
Jordan Virolle, Maximilien Redon, François Montastruc, et al.
Schizophrenia Research (2023) Vol. 262, pp. 184-200
Closed Access | Times Cited: 5
Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer’s disease
Hui Jue Wang, Arun Chinna‐Meyyappan, Oriel J. Feldman, et al.
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 3, pp. 289-303
Closed Access | Times Cited: 1
Hui Jue Wang, Arun Chinna‐Meyyappan, Oriel J. Feldman, et al.
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 3, pp. 289-303
Closed Access | Times Cited: 1
Multiple Adverse Reactions Associated With the Use of Second-Generation Antipsychotics in People With Alzheimer’s Disease: A Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System
Jianxing Zhou, Zipeng Wei, Wei Huang, et al.
Annals of Pharmacotherapy (2024)
Closed Access | Times Cited: 1
Jianxing Zhou, Zipeng Wei, Wei Huang, et al.
Annals of Pharmacotherapy (2024)
Closed Access | Times Cited: 1
Potentially Inappropriate Psychotropic Drugs in Nursing Homes: An Italian Observational Study
Marina Azab, Alessio Novella, Aladar Ianes, et al.
Drugs & Aging (2023) Vol. 41, Iss. 2, pp. 187-197
Closed Access | Times Cited: 3
Marina Azab, Alessio Novella, Aladar Ianes, et al.
Drugs & Aging (2023) Vol. 41, Iss. 2, pp. 187-197
Closed Access | Times Cited: 3
A description of risk associated with use of antipsychotics among community dwelling older adults: A descriptive cross-sectional study
Carlos Ruíz‐González, María del Carmen González‐López, María José García-Ramón, et al.
Geriatric Nursing (2024) Vol. 55, pp. 362-367
Closed Access
Carlos Ruíz‐González, María del Carmen González‐López, María José García-Ramón, et al.
Geriatric Nursing (2024) Vol. 55, pp. 362-367
Closed Access
